# US 2022/0088203 A1 · Glycemic Control Using Intrinsic Factor Bound to A Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088203 A1
- Document ID: US20220088203A1
- Status: Published application
- Kind: A1
- Application number: 17/239,934
- Filed: 2021-04-26
- Published: 2022-03-24
- Earliest claimed: 2015-05-20
- Assignees: Syracuse University
- Applicants: Syracuse University; Xeragenx LLC
- Inventors: Robert Doyle; Jonathan D. Bortz; David S. Hermelin
- Web page: https://patentgrep.com/patent/US20220088203A1

## CPC

- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/26: Glucagons
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.

## Claims

### Claim 1

A method of enhancing a subcutaneously delivered target peptide, comprising the steps of:
a) conjugating a molecule of B12 to the target peptide; and
b) binding intrinsic factor to the conjugate of the molecule of B12 and the target peptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the steps of conjugating the molecule of B12 to the target peptide and binding intrinsic fact to the conjugate are performed prior to subcutaneous administration of the target peptide.

### Claim 3 (depends on 2)

The method of claim 2, wherein the conjugate of the molecule of B12 and the target peptide includes a spacer having between three and six carbon atoms positioned between the molecule of B12 and the target peptide.

### Claim 4 (depends on 3)

The method of claim 3, wherein the target peptide comprises exendin-4.

### Claim 5 (depends on 4)

The method of claim 4, wherein the peptide is conjugated to a 5′ hydroxyl group of the molecule of B12 that has been oxidized to a carboxcylic acid.

### Claim 6

A method to lower blood glucose in a subject, the method comprising subcutaneously or intraperitoneally administering to the subject an effective amount of a pharmaceutical composition comprising intrinsic factor complexed with B12 or an analog thereof, wherein the B12 or analog thereof is conjugated to a peptide comprising a glucagon-like peptide-1 (GLP-1) receptor agonist.

### Claim 7 (depends on 6)

The method of claim 6, wherein the lowering of blood glucose is increased relative to the lowering of blood glucose with the peptide conjugated to B12.

### Claim 8 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable diluents, excipients, and/or carriers.

### Claim 9 (depends on 6)

The method of claim 6, wherein the peptide is conjugated to B12 at the 5′ hydroxyl residue of the ribosyl group.

### Claim 10 (depends on 9)

The method of claim 9, wherein the 5′-hydroxyl of the ribose is oxidized to a carboxylic acid prior to conjugation to the peptide.

### Claim 11 (depends on 6)

The method of claim 6, wherein the B12 or analog thereof is conjugated to the peptide via a linker.

### Claim 12 (depends on 11)

The method of claim 11, wherein the linker comprises between three and six carbon atoms.

### Claim 13 (depends on 11)

The method of claim 11, wherein the linker comprises 4 carbon atoms.

### Claim 14 (depends on 6)

The method of claim 6, wherein the peptide comprises EX-4.

### Claim 15 (depends on 6)

The method of claim 6, wherein the peptide comprises the sequence set forth in SEQ ID NO:1 or SEQ ID NO:2.

### Claim 16 (depends on 15)

The method of claim 15, wherein the peptide comprising SEQ ID NO:1 is conjugated to the 5′-hydroxyl group of the ribose of B12 via the azido group at lysine 12 of the peptide.

### Claim 17 (depends on 6)

The method of claim 6, wherein the IF is purified from a transgenic plant.

### Claim 18

A method of mitigating the effect of TCII sequestration of a B12 conjugate after administration of the conjugate to a subject, the method comprising complexing the B12 conjugate with IF before administering the complex to the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the complex is administered subcutaneously or intraperitonealy.

### Claim 20 (depends on 18)

The method of claim 18, wherein the complex is administered parenterally.
